Landmark TrialRCTRandomized Controlled Trial
Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD
New England Journal of Medicine2016IF: 25.4
Jadwiga A. Wedzicha, Donald Banerji, Kenneth R. Chapman, Jørgen Vestbo, Nicolás Roche, R. Timothy Ayers, Chau Thach, Robert Fogel, Francesco Patalano, Claus Vogelmeier
Abstract
Indacaterol-glycopyrronium was more effective than salmeterol-fluticasone in preventing COPD exacerbations in patients with a history of exacerbation during the previous year. (Funded by Novartis; FLAME ClinicalTrials.gov number, NCT01782326.).